BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1458 related articles for article (PubMed ID: 31333652)

  • 1. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor-specific cytotoxic T lymphocytes.
    El Hage F; Durgeau A; Mami-Chouaib F
    Ann N Y Acad Sci; 2013 Apr; 1283():75-80. PubMed ID: 23302073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
    Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
    J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.
    Durgeau A; El Hage F; Vergnon I; Validire P; de Montpréville V; Besse B; Soria JC; van Hall T; Mami-Chouaib F
    J Immunol; 2011 Dec; 187(11):5532-9. PubMed ID: 22025554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
    Marijt KA; Doorduijn EM; van Hall T
    Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.
    Ashi MO; Mami-Chouaib F; Corgnac S
    Explor Target Antitumor Ther; 2022; 3(6):746-762. PubMed ID: 36654823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.
    Marijt KA; Griffioen L; Blijleven L; van der Burg SH; van Hall T
    Cancer Immunol Immunother; 2022 Feb; 71(2):289-300. PubMed ID: 34142235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.
    Durgeau A; Virk Y; Gros G; Voilin E; Corgnac S; Djenidi F; Salmon J; Adam J; de Montpréville V; Validire P; Ferrone S; Chouaib S; Eggermont A; Soria JC; Lemonnier F; Tartour E; Chaput N; Besse B; Mami-Chouaib F
    Nat Commun; 2018 Nov; 9(1):5097. PubMed ID: 30504837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
    Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
    Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
    Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
    J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
    van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
    Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
    Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with short peptide particles reveals a functional CD8
    He X; Zhou S; Dolan M; Shi Y; Wang J; Quinn B; Jahagirdar D; Huang WC; Tsuji M; Pili R; Ito F; Ortega J; Abrams SI; Ebos JML; Lovell JF
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34862254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.
    Trojan A; Tun-Kyi A; Odermatt B; Nestle FO; Stahel RA
    Lung Cancer; 2002 May; 36(2):151-8. PubMed ID: 11955649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1.
    van Hall T; Laban S; Koppers-Lalic D; Koch J; Precup C; Asmawidjaja P; Offringa R; Wiertz EJ
    J Immunol; 2007 Jan; 178(2):657-62. PubMed ID: 17202325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.
    Lei J; Osen W; Gardyan A; Hotz-Wagenblatt A; Wei G; Gissmann L; Eichmüller S; Löchelt M
    PLoS One; 2015; 10(9):e0138458. PubMed ID: 26397953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.